Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 4
2021 6
2022 3
2023 17
2024 29
2025 34
2026 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Vulsteke C, et al. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. N Engl J Med. 2026. PMID: 41707170 Clinical Trial.
METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy were randomly assigned to perioperative (neoadjuvant and adjuvant) enfortumab vedoti …
METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who were ineligible …
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Galsky MD, et al. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. Future Oncol. 2021. PMID: 34008425 Free article.
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. ...The randomized Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 studies are being conducted to evaluate efficacy an …
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis desp …
Top advances of the year: Bladder cancer.
Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, Chandran E, Simon N. Apolo AB, et al. Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. Cancer. 2025. PMID: 40782344 Review.
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive …
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) …
The Financial Burden of Localized and Metastatic Bladder Cancer.
Scilipoti P, Moschini M, Li R, Lerner SP, Black PC, Necchi A, Rouprêt M, Shariat SF, Gupta S, Morgans AK, Psutka SP, Kamat AM. Scilipoti P, et al. Eur Urol. 2025 May;87(5):536-550. doi: 10.1016/j.eururo.2024.12.002. Epub 2024 Dec 26. Eur Urol. 2025. PMID: 39730299
BACKGROUND AND OBJECTIVE: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. ...Metastatic BCa incurs the highest financial burden, with systemic therapy costs ranging from $40 000 to over $100 000 per five-cycle course, …
BACKGROUND AND OBJECTIVE: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. ...M …
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.
Sternschuss M, Rosenberg JE. Sternschuss M, et al. Future Oncol. 2025 May;21(11):1333-1348. doi: 10.1080/14796694.2025.2482363. Epub 2025 Mar 25. Future Oncol. 2025. PMID: 40129250 Free PMC article. Review.
Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) inhibitor, has become the new st …
Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin- …
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
Wu J, Cheng B, Song Y, Cheng J, Gao H, Luo X, Huang M, Wang F, Du Y, Qin C, Xu T. Wu J, et al. Cancer Res. 2026 Jan 16;86(2):519-539. doi: 10.1158/0008-5472.CAN-25-0024. Cancer Res. 2026. PMID: 41066596
Recently, the combination therapy of enfortumab vedotin (EV), a Nectin-4-targeted antibody-drug conjugate (ADC), with the anti-PD-1 antibody pembrolizumab (EV + pembrolizumab) has shown high and d …
Recently, the combination therapy of enfortumab vedotin (EV), a Nectin-4-targeted antibody-drug …
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Powles T, et al. Ann Oncol. 2024 Jun;35(6):485-490. doi: 10.1016/j.annonc.2024.03.001. Epub 2024 Mar 13. Ann Oncol. 2024. PMID: 38490358 Free article. No abstract available.
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.
van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. van der Heijden MS, et al. ESMO Open. 2025 Aug;10(8):105544. doi: 10.1016/j.esmoop.2025.105544. Epub 2025 Aug 11. ESMO Open. 2025. PMID: 40795788 Free PMC article. Clinical Trial.
BACKGROUND: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated superior efficacy and safety versus platinum-based chemotherapy in patients with previously untreated locally advanced/metastatic urothelial c …
BACKGROUND: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated su …
Antibody-drug conjugates for urothelial carcinoma.
Thomas J, Sun M, Getz T, Ho B, Nauseef JT, Tagawa ST. Thomas J, et al. Urol Oncol. 2023 Oct;41(10):420-428. doi: 10.1016/j.urolonc.2023.06.006. Epub 2023 Jul 6. Urol Oncol. 2023. PMID: 37419845 Review.
Herein, we review the emerging landscape of ADCs in urothelial carcinoma. The anti-Nectin-4 ADC enfortumab vedotin has demonstrated efficacy in prospective studies in patients with advanced urothelial carcinoma in several settings either alone or in co …
Herein, we review the emerging landscape of ADCs in urothelial carcinoma. The anti-Nectin-4 ADC enfortumab vedotin …
Management of metastatic bladder cancer.
Nadal R, Bellmunt J. Nadal R, et al. Cancer Treat Rev. 2019 Jun;76:10-21. doi: 10.1016/j.ctrv.2019.04.002. Epub 2019 Apr 15. Cancer Treat Rev. 2019. PMID: 31030123 Review.
The use of traditional chemotherapy and new immune checkpoints inhibitors (ICIs) directed at programmed cell-death protein 1 (PD-1) or its ligand has led to unprecedented survival benefits in selected patients with metastatic UC. Data show that anti-PD-1 ICIs …
The use of traditional chemotherapy and new immune checkpoints inhibitors (ICIs) directed at programmed cell-death protein 1 (PD-1) or its l …
129 results